At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address autoimmune and inflammatory conditions.

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...

The JV has been formed German pharma companies Boehringer Ingelheim and Evotec with in ... The companies behind Lyon, France-based Aurobac said the JV will combine their respective strengths ...

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug ...

Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net sales Company prepares new product launches starting in 2025 Boehringer Ingelheim ...